Drug Interaction Report

ADJUST DOSE: Coadministration of momelotinib with rosuvastatin may increase the plasma concentration and effects of rosuvastatin. The proposed mechanism is decreased rosuvastatin clearance due to momelotinib-mediated inhibition of the intestinal and hepatobiliary efflux transporter, breast cancer resistance protein (BCRP). Clinical studies have demonstrated that concomitant use of a single dose of rosuvastatin (10 mg) with multiple daily doses of momelotinib (200 mg) increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 220% and 170%, respectively.

MANAGEMENT: If used concomitantly with momelotinib, it is recommended that rosuvastatin be commenced at a dose of 5 mg daily, up to a maximum of 10 mg daily. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.